Recently Featured

Ex-Intercept CEO Takes Over at Altimmune; Carolyn Bertozzi Leaves Alnylam’s Board

December 12, 2025
Vipin Garg, the current CEO of Altimmune, will transition leadership to chairman Jerry Durso effective January 1. Durso, who has been on the board since February, succeeds Mitchel Sayare, marking a significant shift in the company’s executive landscape. This leadership change comes at a pivotal moment as Altimmune seeks to enhance its strategic direction and…

Praxis Halts Pivotal Trial of Rare Epilepsy Drug Relutrigine Early for Efficacy

December 12, 2025
Praxis Precision Medicines has made the significant decision to halt its Phase 2/3 EMBOLD study of relutrigine, a sodium channel modulator aimed at treating a rare form of epilepsy, based on an interim analysis indicating strong efficacy. This early termination reflects the drug’s potential to meet critical efficacy endpoints, which could reshape treatment paradigms for…

Muscle Stem Cells Bolstered by ECM Protein Tenascin-C

December 12, 2025
Recent research highlights the pivotal role of Tenascin-C (TnC), an extracellular matrix protein, in enhancing muscle stem cell function and maintenance, particularly in the context of aging. Sarcopenia, characterized by a decline in muscle mass and function, poses significant health risks for the elderly, making this discovery particularly relevant for healthcare professionals focused on improving…

Denali Secures $275 Million Royalty Funding Agreement with Royalty Pharma

December 11, 2025
Denali has entered into a significant $275 million royalty funding agreement with Royalty Pharma, linked to the anticipated future net sales of its tividenofusp alfa therapy. This strategic financial arrangement underscores the growing confidence in Denali’s pipeline and the potential of its therapeutic offerings, particularly in treating neurological disorders. The partnership with Royalty Pharma not…

Ongoing Cases